Starna Scientific Ltd is the manufacturing headquarters of the Starna range of specialised products, which include photometer cells and accessories, optical components and Certified Reference materials to ISO/IEC 17025 standards.
Starna Scientific’s Reference Material and Calibration manufacturing laboratory has extended the Starna range of Certified Reference Materials (CRMs), providing the most comprehensive range of UV/Visible/NIR Materials currently available under the scope of ISO Guide 34 + ISO/IEC 17025 accreditation for Reference Material producers.
"We now hold a unique position in the production of CRMs for wavelength and Transmittance scales, certified in accordance with ISO Guide 34 and ISO/IEC 17025, for the complete Far UV to NIR spectral region (190 – 2850 nm)," explained Keith Hulme, Starna's Managing Director.
The Starna® Lifetime Guarantee is offered on all Starna® manufactured Certified Reference Materials (CRMs). The guarantee provides for a free of charge replacement should the assigned values move outside the expanded uncertainty budget within the recertification period of two years, subject to conditions of use/care and recertification by Starna at least every two years.
The CRMs are essential for ISO/IEC accredited laboratories, pharmaceutical QA/QC or metrology departments enabling the provision of Operational Qualification (OQ) and Performance Qualification (PQ) of UV/Visible/NIR instrumentation using 'Industry Standard' protocols.
Starna is the only Reference Material producer accredited to both ISO Guide 34 and ISO/IEC 17025 in the UV/Visible/NIR spectral range. The CRMs the company now provide extend the scope of available materials for spectral range, band width and photometric linearity.
Visit www.starna.com, email sales@starna.com or call + 44 (0) 20 8501 5550 for more information.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.